Pancreatic cancer represents one of the most lethal solid tumors, which is notoriously refractory to chemotherapy. Thus, the therapy outcome for patients with pancreatic cancer is still poor. A large number of new treatment approaches are being investigated actively, and antibody-drug conjugates (ADCs) showing unique advantages has been widely assessed in the treatment of pancreatic cancer.
